Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

[1]  P. Reaven,et al.  Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins , 2011, Cardiovascular diabetology.

[2]  H. Grill,et al.  Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. , 2011, Endocrinology.

[3]  A. Dear,et al.  A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model , 2011, Diabetes & vascular disease research.

[4]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[5]  Y. Nakaya,et al.  Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. , 2009, Biochemical and biophysical research communications.

[6]  D. Matthews,et al.  Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue , 2009, Diabetes, obesity & metabolism.

[7]  D. Andersen,et al.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  Weiping Jia,et al.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.

[9]  F. Hu,et al.  Dietary Fat Intake and Cognitive Decline in Women With Type 2 Diabetes , 2009, Diabetes Care.

[10]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[11]  Y. Seino,et al.  Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[12]  Jennifer G. Robinson,et al.  Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. , 2008, Archives of internal medicine.

[13]  L. B. Knudsen,et al.  Liraglutide, a Once‐daily Human Glucagon‐like Peptide‐1 Analog, Minimizes Food Intake in Severely Obese Minipigs , 2007, Obesity.

[14]  Parvez Hossain,et al.  Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.

[15]  Tanya Hansotia,et al.  Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.

[16]  L. B. Knudsen,et al.  Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.

[17]  Makoto Nishida,et al.  A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. , 2005, Diabetes care.

[18]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[19]  J. Holst,et al.  The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. , 2004, Diabetes.

[20]  J. Manson,et al.  Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. , 2004, The American journal of clinical nutrition.

[21]  S. Kihara,et al.  Adiponectin and Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  R. Mensink,et al.  Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.

[23]  Anastasia C. Thanopoulou,et al.  Dietary fat intake as risk factor for the development of diabetes: multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD). , 2003, Diabetes care.

[24]  R. Bergman,et al.  Accurate Assessment of β-Cell Function: The Hyperbolic Correction , 2002 .

[25]  M. Zdravkovic,et al.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men , 2002, Diabetologia.

[26]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  D R Jacobs,et al.  Dietary fat and incidence of type 2 diabetes in older Iowa women. , 2001, Diabetes care.

[28]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[29]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[30]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[31]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[32]  R. Hamman,et al.  High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. , 1991, American journal of epidemiology.

[33]  D. Leonetti,et al.  Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes. , 1990, The American journal of clinical nutrition.

[34]  P. Bennett,et al.  Diabetes Mellitus and Its Vascular Complications in Japanese Migrants on the Island of Hawaii , 1979, Diabetes Care.

[35]  A. Dear,et al.  Erratum: A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model (Diabetes and Vascular Disease Research (2011) 8:2 (117-124) DOI: 10.1177/1479164111404257) , 2012 .

[36]  R. Chilton,et al.  Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. , 2011, The American journal of medicine.

[37]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[38]  R. Bergman,et al.  Accurate assessment of beta-cell function: the hyperbolic correction. , 2002, Diabetes.